Đang chuẩn bị liên kết để tải về tài liệu:
Biomedical Engineering Trends Research and Technologies Part 5

Tham khảo tài liệu 'biomedical engineering trends research and technologies part 5', kỹ thuật - công nghệ, cơ khí - chế tạo máy phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả | 7 Clinical Application of Automatic Gene Chip Analyzer WEnCA-Chipball for Mutant KRAS Detection in Peripheral Circulating Tumor Cells of Cancer Patients Suz-Kai Hsiung1 2 Shiu-Ru Lin1 2 Hui-Jen Chang1 2 Yi-Fang Chen3 and Ming-Yii Huang4 5 1Department of Medical Research Fooyin University Hospital Pingtung 2School of Medical and Health Science Fooyin University Koahsiung 3Gene Target Technology Co.Ltd Koahsiung Department of Radiation Oncology Kaohsiung Medical University Hospital Kaohsiung Department of Radiation Oncology Faculty of Medicine College of Medicine Kaohsiung Medical University Kaohsiung Taiwan ROC 1. Introduction KRAS is an important oncogene that participates in the mitogen-activated protein kinase MAPK pathway. The MAPK pathway is involved in various cellular functions including cell proliferation differentiation and migration. Mutations in KRAS are found in many types of malignancies including lung cancer Fong et al. 1998 Slebos Rodenhuis 1989 Chen et al. 2003 Siegfried et al. 1997 colorectal cancer Calistri et al. 2006 Weijenberg et al. 2008 Wang et al. 2007 and pancreatic cancer Smit et al. 1988 Gocke et al. 1997 . As early as 1989 Slebos et al. have identified that the KRAS mutation status can be used for lung cancer detection or prognosis prediction Slebos Rodenhuis 1989 . In 1995 Yakubovskaya et al. detected 12 different KRAS mutations in nearly 60 of tissue specimens of non-small cell lung cancer NSCLC patients Yakubovskaya et al. 1995 . As for pancreatic stomach and breast cancers there have been a number of studies reporting KRAS mutations Smit et al. 1988 Gocke et al. 1997 Deramaudt Rustgi 2005 Carstens et al. 1988 Lee et al. 2003 Shen et al. 2008 . The predictive value of KRAS mutation in metastatic colorectal cancer patients treated with cetuximab plus chemotherapy has recently been shown in that patients with tumor KRAS mutation were resistant to cetuximab and had shorter progression survival and overall survival times compared with .